Eribulin shows increased benefit among women sharing certain traits

[News]

Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits.

More... (http://www.news-medical.net/news/20130613/Eribulin-shows-increased-benefit-among-women-sharing-certain-traits.aspx)